Abstract:Objective: Assess the 4-year antibody against hepatitis B surface antigen (anti-HBs) persistence after revaccination with 3-dose of hepatitis B vaccine (HepB) among low-responder infants following primary vaccination. Methods: According to stratified cluster sampling, a total of 4 147 infants were enrolled and primarily vaccinated with 5 μg HepB derived in Saccharomyces Cerevisiae (HepB-SC) at 0-1-6 months schedule from 75 towns of Jinan, Weifang, Yantai, Weihai prefectures, Shandong Province, China in Aug and Sep 2009. Blood samples were collected one to six months after the third dose of primary immunization and tested for anti-HBs using chemiluminescence microparticle immunoassay (CMIA). 717 infants who appeared low response (10 mU/ml ≤ anti-HBs<100 mU/ml) were revaccinated with 3-dose of HepB. Blood samples were collected from a total of 315 infants one month (T(0)), four years (T(1)) after revaccination and anti-HBs, antibody against hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were detected by CMIA. Information about their birth, primary vaccination were collected. The risk factors associated with positive rate of anti-HBs and GMC of anti-HBs were identified by multiple non-conditional logistic regression analysis and multifactor linear regression model analysis, respectively. Results: Among 315 children, 165 (52.38%) were male and 150 (47.62%) were female. The positive rate was 83.81% (264/315) at T(0) and it decreased to 16.51% (149/529) at T(1). The corresponding GMC decreased from 473.15 mU/ml to 17.37 mU/ml. The average annual decreasing rate of positive rate and GMC was 33.38% and 56.23% from T(0) to T(1). Multivariable analysis showed the positive rate and GMC among those whose anti-HBs titer higher at T(0) were significantly higher at T(1). The positive rate at T(1) among those whose anti-HBs titer 400-<600, 600-<800, 800-<1 000, ≥1 000 mU/ml at T(0) were significantly higher than those whose anti-HBs titer less than 200 mU/ml. The OR (95%CI) of the positive rate was 4.29 (1.03-17.84), 4.53 (1.25-16.47), 4.19 (1.10-15.97) and 9.13 (2.91-28.63), respectively. The GMC at T(1) among those whose anti-HBs titer 400-<600, 600-<800, 800-<1 000 mU/ml and those whose anti-HBs titer ≥1 000 mU/ml at T(0) were higher than those whose anti-HBs titer<200 mU/ml. The b value (95% CI) of GMC was 0.84 (0.06-1.62), 1.13 (0.46-1.79), 1.33 (0.65-2.01) and 1.88 (1.33-2.44), respectively. GMC among full-term infants were significantly higher than premature infants at T(1). The b value (95% CI) of GMC was 0.86 (0.04-1.68). Conclusion: Anti-HBs GMC decreased rapidly 4 years after revaccination among low-responder infants, but still kept good protection. The anti-HBs persistence after revaccination was associated with anti-HBs level of titer one month after revaccination.

Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Modeling Long-Term Persistence after 8 Years of Hepatitis B Booster Vaccination in 5- to 15-Year-old Children

[Long-term efficacy and persistence of Chinese infants after receiving only active plasma-derived hepatitis B vaccine]

[Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among low-responder infants following primary vaccination: 4-year of follow-up]

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

The long-term efficacy of recombinant hepatitis B vaccines for children

Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

The effects of booster vaccination of hepatitis B vaccine on anti-HBs negative children 11-15 years after primary vaccination

Long-term Persistence of Anti-Hbs after Hepatitis B Vaccination among Isolated Anti-Hbc Positive Adults in China: 8-Years Results

Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data

Persistence of Anti-HAV Antibody and Long-Term Protection Conferred by a Single Dose of Live-Attenuated Hepatitis a Vaccine: Results from 17-Year Follow-Up

Immune Memory at 17-Years of Follow-Up of a Single Dose of Live Attenuated Hepatitis A Vaccine.

Long-term Persistence of Anti-Hav Antibody Conferred by a Single Dose of Live-Attenuated Hepatitis A Vaccine: Results from 17-Year Follow-Up.

Effects of hepatitis B vaccine boosters in different levels of epidemic areas on anti-HBs-negative children after primary vaccination

Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study